P. Banks

发表

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Shivakumar Keerthikumar, N. Lawrentschuk, R. Pearson, 2018, European urology.

Relevance of DNA damage repair in the management of prostate cancer.

D. Murphy, P. James, S. Sandhu, 2017, Current problems in cancer.

Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

D. Rischin, S. Sandhu, D. Gyorki, 2016, Journal of oncology practice.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies

Douglas B. Johnson, L. Haydu, M. Millward, 2019, Pigment cell & melanoma research.

Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series

G. McArthur, M. Shackleton, A. Lasocki, 2019, Health science reports.

Characteristics of cancer diagnoses and staging in South Western Victoria: a rural perspective.

L. Matheson, D. Ashley, M. Henry, 2014, The Australian journal of rural health.

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

L. Horvath, T. Akhurst, I. Davis, 2021, Annals of Oncology.

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

S. Lade, N. Lawrentschuk, D. Murphy, 2022, Journal for ImmunoTherapy of Cancer.

Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.

M. Bulsara, A. Redfern, Patricia D Banks, 2021, The Cochrane database of systematic reviews.